Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective

Published:1998-11 Issue:12 Volume:34 Page:1894-1901
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Berger K.,Fischer T.,Szucs T.D.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. International Agency for Research on Cancer. Facts and figures of cancer in the European community. Lyon, 1993.

2. Estimates of the worldwide incidence of eighteen major cancers in 1985;Parkin;Int J Cancer,1993

3. Current drug treatment guidelines for epithelial ovarian cancer;Lorigan;Drugs,1996

4. Allen DG, Baak J, Belpomme D, et al. Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol 1993, 4(Suppl. 4), 83–88.

5. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer;Spencer;Drugs,1994

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bevacizumab in ovarian cancer: A critical review of phase III studies;Oncotarget;2016-11-11

2. Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage III C and IV epithelial ovarian cancer;ClinicoEconomics and Outcomes Research;2016-08

3. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review;PharmacoEconomics;2015-06-14

4. Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer;Value in Health;2015-06

5. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation;Health Technology Assessment;2015-01